These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35071113)

  • 1. A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.
    Puthenpurail A; Rathi H; Nauli SM; Ally A
    World J Pharm Pharm Sci; 2021 Nov; 10(11):14-22. PubMed ID: 35071113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marketed therapeutic antibodies compendium.
    Reichert JM
    MAbs; 2012; 4(3):413-5. PubMed ID: 22531442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic monoclonal antibodies in ophthalmology.
    Rodrigues EB; Farah ME; Maia M; Penha FM; Regatieri C; Melo GB; Pinheiro MM; Zanetti CR
    Prog Retin Eye Res; 2009 Mar; 28(2):117-44. PubMed ID: 19114125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials.
    Heliopoulos I; Patousi A
    Med Chem; 2018 Feb; 14(2):144-154. PubMed ID: 28875861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.
    Vacchelli E; Aranda F; Eggermont A; Galon J; Sautès-Fridman C; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2014 Jan; 3(1):e27048. PubMed ID: 24605265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody treatments for multiple sclerosis.
    Rose JW; Foley JF; Carlson NG
    Curr Treat Options Neurol; 2009 May; 11(3):211-20. PubMed ID: 19364456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.
    Arlen M; Arlen P; Tsang A; Wang X; Gupta R
    J Cancer; 2010 Nov; 1():209-22. PubMed ID: 21060731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new era for monoclonal antibodies with applications in neurology (Review).
    Sirbu CA; Ghinescu MC; Axelerad AD; Sirbu AM; Ionita-Radu F
    Exp Ther Med; 2021 Jan; 21(1):86. PubMed ID: 33363597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors.
    Argyriou AA; Kalofonos HP
    Mol Med; 2009; 15(5-6):183-91. PubMed ID: 19305491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics interactions of monoclonal antibodies.
    Ferri N; Bellosta S; Baldessin L; Boccia D; Racagni G; Corsini A
    Pharmacol Res; 2016 Sep; 111():592-599. PubMed ID: 27438459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.
    Santoro D; Pellicanò V; Visconti L; Trifirò G; Cernaro V; Buemi M
    Expert Opin Biol Ther; 2015; 15(8):1119-43. PubMed ID: 26087994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
    Bugelski PJ; Martin PL
    Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.
    Suárez I; Salmerón-García A; Cabeza J; Capitán-Vallvey LF; Navas N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():155-164. PubMed ID: 27296731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of antibody therapy in demyelinating diseases.
    Akaishi T; Nakashima I
    Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents].
    Komada F; Nakayama Y; Takara K
    Yakugaku Zasshi; 2018; 138(12):1587-1594. PubMed ID: 30504674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].
    Bodmer A; Goetsch L; Favet L; Bailly C; Corvaia N; Dietrich PY
    Med Sci (Paris); 2009 Dec; 25(12):1090-8. PubMed ID: 20035684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.
    Trebst C; Voss E; Skripuletz T; Stangel M
    Curr Med Chem; 2010; 17(7):640-50. PubMed ID: 20088763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease.
    Willeman T; Jourdil JF; Gautier-Veyret E; Bonaz B; Stanke-Labesque F
    Anal Chim Acta; 2019 Aug; 1067():63-70. PubMed ID: 31047150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.